Certolizumab pegol in severe rheumatoid arthritis. Real-life evidence in an Argentine cohort: goal achievement (t2t) at 3 months and predictive factors.
22 October, 2023
09 February, 2024
Cite as:
Citar como
Garcia Salinas R, Magri S, Ruta A. Certolizumab pegol en artritis reumatoidea severa. Evidencia de la vida real en una cohorte argentina: Logro de objetivos (T2T) a 3 meses y factores predictivos. Global Rheumatology. Vol 5/ Ene - Jun [2024]. Available from: https://doi.org/10.46856/grp.10.e182
Views
501Views
License
This is an open-access article distributed by the terms of the Creative Common Attribution License (CC-BY NC-4). The use, distribution or reproduction in other forms is permitted, provided the original author(a) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with this terms.
